On Aug. 17, 2011, Genentech announced that Elborafﾮ (vemurafenib) was approved by the FDA for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test. A diagnostic test developed by Roche to identify patients eligible for Zelboraf treatment was also approved.